Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors as it is primarily excreted via the biliary/gastrointestinal route rather than the kidneys.
## Primary Indications
Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
5 mg orally once daily, taken with or without food.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients (under 18 years). Use is not recommended.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
* **Elderly:** No dose adjustment required.
## Contraindications
* Hypersensitivity to linagliptin or any component of the formulation.
* History of pancreatitis.
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or secretagogues).
* **Serious:** Acute pancreatitis (including fatal cases), severe and disabling arthralgia, bullous pemphigoid, hypersensitivity reactions (angioedema, urticaria).
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin efficacy. Avoid combination or monitor glycemic control closely if combined.
* **Insulin/Insulin Secretagogues (Sulfonylureas):** Increased risk of hypoglycemia; a reduction in the secretagogue dose may be required.
## Monitoring
* **HbA1c:** Every 3–6 months.
* **Pancreatitis:** Monitor for persistent, severe abdominal pain radiating to the back.
* **Skin:** Monitor for blistering or erosions suggestive of bullous pemphigoid.
* **Joint Pain:** Assess if patients report new or worsening severe joint pain.
## Clinical Pearls
* Linagliptin is the only DPP-4 inhibitor that does not require renal dose adjustments, making it useful for patients with advanced chronic kidney disease or end-stage renal disease.
* It does not cause weight gain.
* If pancreatitis is suspected, discontinue the drug immediately and do not restart.
* Tablets should be swallowed whole; do not split or crush.
***
**Educational Disclaimer:** This information is for educational purposes and does not constitute medical advice. Always verify current prescribing information, official package inserts, and local institutional protocols before initiating therapy.
